- Home >
- Clinicals Trials >
- AV-299-23-301
Back to clinical trials listENT/Head and Neck Cancers
AV-299-23-301
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF FICLATUZUMAB IN COMBINATION WITH CETUXIMAB IN PARTICIPANTS WITH RECURRENT OR METASTATIC (R/M) HPV-NEGATIVE HEAD AND NECK SQUAMOUS CELL CARCINOMA (FIERCE-HN)
- Open at Paris since : 05/12/2024
- Target : Adult
- Phase : Phase III
Trial description
To compare the efficacy by overall survival of ficlatuzumab plus cetuximab vs placebo plus cetuximab in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).Overall survival (OS), defined as the time from the date of randomization to the date of death for any cause.
Url of the trial